- Hypertrophic Cardiomyopathy (HCM)
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
GAO report finds concentration of insurers, lack of competition in most state markets
In at least 37 states, the three largest insures account for 80% of total health plan enrollment, according to a new study by the U.S. Government Accountability Office (GAO).
In at least 37 states, the three largest insures account for 80% of total health plan enrollment, according to a new study by the U.S. Government Accountability Office (GAO).
In ten states, a single insurer had more than half of all enrollees, and in five states, one insurer had at least 90% of either the individual, small group or large group enrollee segment, according to the report.
A highly concentrated market, where a small number of insurers enroll a significant portion of the population, can lead to lack of competition that could affect consumers’ choice of health plans and premiums.
READ: AMA study finds significant lack of health insurer competition in 72% of metropolitan areas
GAO analyzed enrollment data from 2010 to 2013 that was reported to the National Association of Insurance Commissioners (NAIC) and the Centers for Medicare and Medicaid Services (CMS). The agency provided the report to the U.S. Health and Human Services Department (HHS), but didn’t make any recommendations or comments.
The report also found that insurers’ concentration in the three market segments – individual, small group and large group – remained relatively unchanged form 2010 to 2013. On average, twice as many insurers participated in the individual segment than in the small group or large group.
In 12 states where there was less market dominance, there was an average 30 insurers in the individual market, 16 in the small group market, and 17 in the large group market. In nearly all of these states’ market segments, the largest insurer had less than half of the total enrollment, according to GAO.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More
